Indonesia Screens for Diabetes at Posyandu Posts That Cannot Prescribe Metformin
Indonesia has built one of the world's largest community screening networks for type-2 diabetes. It has not built a matching treatment pathway. At tens of thousands of posyandu posts, unpaid village cadres measure blood glucose, record the number in a paper register, and tell anyone with a high reading to visit a puskesmas. The cadre cannot hand over a single metformin tablet. That gap between detection and treatment is the central design flaw in Indonesia's non-communicable disease response.
Screening Without Treatment Rights
Posyandu cadres operate under village-level authority that covers weighing, measuring, and basic counselling. Blood glucose screening was added to their remit as non-communicable diseases climbed the national burden. What was not added was any dispensing authority. Indonesian pharmacy law restricts the supply of prescription medicines to licensed facilities and licensed personnel, which means a cadre who confirms a high reading has no legal route to provide the first-line drug.
The practical consequence is a referral. The cadre writes the result in a register, advises the patient to go to the nearest puskesmas, and the encounter ends there. Puskesmas doctors can prescribe metformin, and the national health insurance scheme, JKN, generally covers it. But the distance between a village post and a puskesmas can be substantial, and no transport subsidy accompanies the advice.
Referral completion is not systematically tracked at national level. A positive screening result is recorded at the posyandu, but whether that person ever reaches a prescriber is largely unknown. This is the difference between a screening programme and a detection programme: one follows the patient, the other counts the test.
How Posyandu Became Diabetes Frontline
Posyandu began as integrated health posts focused on maternal and child health: weighing infants, tracking growth, providing immunisation and nutrition advice. Over time, as life expectancy rose and diets shifted, the same posts were asked to absorb adult screening for hypertension and diabetes. The infrastructure was already there, and the cadres were already trusted in their communities.
Cadres remain unpaid volunteers. Training is short and infrequent, and the equipment is often donated. Glucometers arrive through district health offices, non-governmental organisations, or corporate social responsibility programmes. Test strips are the recurring problem: they are consumable, they expire, and they are frequently out of stock. A cadre with a working meter and no strips cannot screen anyone.
The result is a screening network that is broad but uneven. Some districts have functioning monthly diabetes screening; others screen only when strips are available. Because cadres are volunteers, their availability varies with their own work and family obligations. The system depends on goodwill, and goodwill does not restock consumables.
Take Central Java, where several districts have integrated non-communicable disease screening into their posyandu. In these areas, cadres often use a simple risk questionnaire before offering a blood glucose test, a triage step that helps conserve strips. But even with triage, the follow-up problem persists: a high reading on a questionnaire does not guarantee a visit to a clinic. The district health office may compile monthly reports on the number of screenings, but not on the number of patients who subsequently receive a diagnosis or prescription. This data gap makes it difficult to assess whether the programme is improving health outcomes or simply generating paperwork.
The Regulation That Blocks Treatment
Indonesia's pharmacy regulations exist to protect patients from unsafe dispensing, and the restriction on who can supply prescription medicines is not arbitrary. Cadres receive limited training and are not clinically supervised in the way nurses or pharmacists are. Allowing them to dispense metformin would create a parallel supply chain with weak oversight, and metformin is not risk-free for everyone.
That objection is legitimate. The counter-argument is that the current arrangement also carries risk: a person with a confirmed high glucose reading who never reaches a prescriber faces the long-term complications of untreated type-2 diabetes, including kidney damage, retinopathy, and poor wound healing. The regulatory line protects against one harm while leaving another unaddressed.
Puskesmas doctors can prescribe, but their reach is limited by geography and staffing. In many districts, a single puskesmas serves a wide catchment, and doctors are stretched across maternal care, infectious disease, and administrative duties. A related piece on this site describes how Brazil's free diabetes medicines stop at the border of Amazonas, a reminder that supply chains and prescribing authority are separate problems that often compound each other.
What Happens After a High Reading
When a cadre records a high reading, the immediate action is verbal advice. The patient is told to visit the puskesmas, sometimes with a written note, sometimes without. There is no appointment, no reminder system, and no transport support. For a daily-wage worker, a day lost to travel is a day without income, and the cost of getting to a clinic can exceed the cost of the medicine itself.
Some patients respond by buying metformin informally from pharmacies or roadside stalls. Without a prescription, the dose may be wrong, the product may be counterfeit, and there is no follow-up. But it reflects a rational calculation: the informal route is faster and often cheaper than the formal one, even if it is less safe.
The screening register itself is a paper document in most posyandu. Data may be summarised at the district level, but linking an individual screening result to a JKN enrolment record or a subsequent prescription is not standard practice. Without that link, the system cannot tell whether its own referrals work.
Pilot Programs Testing Task-Shifting
Several districts have begun testing nurse-led diabetes clinics, where nurses initiate or adjust metformin under standing orders or remote physician supervision. This is a form of task-shifting: moving a clinical task to a less specialised cadre with clear protocols and oversight. Early experience suggests it can extend reach, though the evidence base on cadre-led refills specifically remains thin.
International agencies, including the World Health Organization and the World Bank, have supported integration of non-communicable disease care into primary health services. The WHO has also renewed partnership agreements with the African Union on health-systems strengthening, which is a different region but illustrates the same operational principle: screening without a treatment pathway does not change outcomes.
Indonesia's JKN scheme covers metformin, which solves the affordability problem for enrolled patients who reach a prescriber. It does not cover outreach, transport, or the cadre time that makes screening possible. A related piece on this site notes that cervical cancer screening reaches cities while rural clinics wait on pathology; the pattern of detection outpacing treatment capacity is not unique to diabetes.
One promising variant is the 'desa siaga' (alert village) model, where district health offices partner with village governments to fund a small incentive for cadres who complete a set number of screenings and referrals each month. In districts that have tried it, the extra income is modest but regular, and it has helped stabilise the volunteer roster. The trade-off is that incentives tied to screening numbers can encourage quantity over quality; a cadre might test more people while spending less time on counselling. Getting the design right requires careful monitoring, which itself costs money.
Practical Steps for Policymakers
Authorize nurse-initiated metformin at puskesmas level, with standing orders and a defined supervision relationship, so that a confirmed high reading can be converted into a prescription without waiting for a doctor's separate consultation.
Fund glucose test strips through village health budgets rather than relying on donations, because consumables that depend on goodwill run out. A screening post without strips is a building, not a service.
Link posyandu screening registers to JKN enrolment data so that referral completion can be measured. Without that link, districts cannot tell whether their screening programme is working or merely active.
Train cadres on referral navigation, not prescribing. Their value is in finding people and getting them to care, and that task deserves a defined protocol, a checklist, and a follow-up call or visit.
Evaluate pilot districts before national scale-up. Task-shifting works in some settings and fails in others, and the difference is usually supervision, supply, and whether anyone is counting the patients who never arrive.
This article is informational and does not constitute personalised medical advice. Readers with concerns about blood glucose or diabetes treatment should consult a qualified health professional.
